Impaired PGC-1α function in muscle in Huntington's disease
Open Access
- 21 May 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 18 (16) , 3048-3065
Abstract
We investigated the role of PPAR γ coactivator 1α (PGC-1α) in muscle dysfunction in Huntington's disease (HD). We observed reduced PGC-1α and target genes expression in muscle of HD transgenic mice. We produced chronic energy deprivation in HD mice by administering the catabolic stressor β-guanidinopropionic acid (GPA), a creatine analogue that reduces ATP levels, activates AMP-activated protein kinase (AMPK), which in turn activates PGC-1α. Treatment with GPA resulted in increased expression of AMPK, PGC-1α target genes, genes for oxidative phosphorylation, electron transport chain and mitochondrial biogenesis, increased oxidative muscle fibers, numbers of mitochondria and motor performance in wild-type, but not in HD mice. In muscle biopsies from HD patients, there was decreased PGC-1α, PGC-1β and oxidative fibers. Oxygen consumption, PGC-1α, NRF1 and response to GPA were significantly reduced in myoblasts from HD patients. Knockdown of mutant huntingtin resulted in increased PGC-1α expression in HD myoblast. Lastly, adenoviral-mediated delivery of PGC-1α resulted increased expression of PGC-1α and markers for oxidative muscle fibers and reversal of blunted response for GPA in HD mice. These findings show that impaired function of PGC-1α plays a critical role in muscle dysfunction in HD, and that treatment with agents to enhance PGC-1α function could exert therapeutic benefits. Furthermore, muscle may provide a readily accessible tissue in which to monitor therapeutic interventions.Keywords
This publication has 79 references indexed in Scilit:
- N-Terminal Mutant Huntingtin Associates with Mitochondria and Impairs Mitochondrial TraffickingThe Journal of Neuroscience, 2008
- AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1αProceedings of the National Academy of Sciences, 2007
- PGC-1α regulates the neuromuscular junction program and ameliorates Duchenne muscular dystrophyGenes & Development, 2007
- Cardiac dysfunction in the R6/2 mouse model of Huntington’s diseaseNeurobiology of Disease, 2007
- PGC-1α protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcriptionProceedings of the National Academy of Sciences, 2006
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences, 2005
- PGC-1α Deficiency Causes Multi-System Energy Metabolic Derangements: Muscle Dysfunction, Abnormal Weight Control and Hepatic SteatosisPLOS Biology, 2005
- PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetesNature Genetics, 2003
- Transcriptional co-activator PGC-1α drives the formation of slow-twitch muscle fibresNature, 2002
- Targeting functional subtypes of spinal motoneurons and skeletal muscle fibers in vivo by intramuscular injection of adenoviral and adeno-associated viral vectorsBrain Structure and Function, 2002